Loading...
•
Mar 31, 2022
Keros Q1 2022 Earnings Report
Keros Therapeutics reported financial results for the first quarter of 2022.
Key Takeaways
Keros Therapeutics reported a net loss of $24.2 million in the first quarter of 2022, compared to a net loss of $15.9 million in the first quarter of 2021. The increase in net loss was largely due to increased research and development efforts and additional infrastructure expenses.
Keros reported a net loss of $24.2 million in the first quarter of 2022.
Research and development expenses were $18.1 million for the first quarter of 2022.
Cash and cash equivalents as of March 31, 2022 was $228.6 million.
Keros expects that the cash and cash equivalents it had on hand at March 31, 2022 will fund its operating expenses and capital expenditure requirements into the first quarter of 2024.
Forward Guidance
Keros expects that the cash and cash equivalents it had on hand at March 31, 2022 will fund its operating expenses and capital expenditure requirements into the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...